NASDAQ:ASMBAssembly Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Assembly Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $22.20 -0.18 (-0.80 %) (As of 07/31/2020 04:00 PM ET) Add Compare Share Today's Range$21.31Now: $22.20▼$22.3850-Day Range$20.47MA: $23.02▼$27.0452-Week Range$8.13Now: $22.20▼$27.84Volume226,968 shsAverage Volume213,804 shsMarket Capitalization$726.38 millionP/E RatioN/ADividend YieldN/ABeta1.29 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in two Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in investigational new drug-enabling studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, and immuno-oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAssembly Biosciences has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.00, Assembly Biosciences has a potential upside of 93.7% from its current price of $22.20.Amount of Analyst CoverageAssembly Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesAssembly Biosciences has received 226 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAssembly Biosciences has received 261 “underperform” votes. (Add your “underperform” vote.)Community SentimentAssembly Biosciences has received 53.59% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote “Outperform” if you believe ASMB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Assembly Biosciences is held by insiders.Percentage Held by Institutions88.31% of the stock of Assembly Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Assembly Biosciences are expected to decrease in the coming year, from ($2.05) to ($3.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.34 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ASMB Previous Symbol CUSIP92282210 CIK1426800 Webwww.assemblybio.com Phone833-509-4583Debt Debt-to-Equity Ratio0.03 Current Ratio12.14 Quick Ratio12.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.96 million Price / Sales45.51 Cash FlowN/A Price / Cash FlowN/A Book Value$10.49 per share Price / Book2.12Profitability EPS (Most Recent Fiscal Year)($3.72) Net Income$-97,630,000.00 Net Margins-601.75% Return on Equity-45.43% Return on Assets-34.79%Miscellaneous Employees95 Outstanding Shares32,720,000Market Cap$726.38 million Next Earnings Date8/3/2020 (Estimated) OptionableOptionable $22.20 -0.18 (-0.80 %) (As of 07/31/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ASMB News and Ratings via Email Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions How has Assembly Biosciences' stock been impacted by COVID-19 (Coronavirus)? Assembly Biosciences' stock was trading at $15.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASMB shares have increased by 42.3% and is now trading at $22.20. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Assembly Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Assembly Biosciences. When is Assembly Biosciences' next earnings date? Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Assembly Biosciences. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences Inc (NASDAQ:ASMB) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.98) by $0.22. The biopharmaceutical company earned $4.08 million during the quarter, compared to analysts' expectations of $3.82 million. Assembly Biosciences had a negative net margin of 601.75% and a negative return on equity of 45.43%. View Assembly Biosciences' earnings history. What price target have analysts set for ASMB? 5 brokers have issued 1 year price objectives for Assembly Biosciences' stock. Their forecasts range from $30.00 to $74.00. On average, they expect Assembly Biosciences' stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 93.7% from the stock's current price. View analysts' price targets for Assembly Biosciences. Has Assembly Biosciences been receiving favorable news coverage? News stories about ASMB stock have been trending negative on Monday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Assembly Biosciences earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Assembly Biosciences. Who are some of Assembly Biosciences' key competitors? Some companies that are related to Assembly Biosciences include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), FibroGen (FGEN), Gilead Sciences (GILD), Lexicon Pharmaceuticals (LXRX), Nektar Therapeutics (NKTR) and Agile Therapeutics (AGRX). Who are Assembly Biosciences' key executives? Assembly Biosciences' management team includes the following people: Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 43)Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 47)Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 69)Mr. Thomas E. Rollins, Exec. Officer (Age 63)Mr. David J. Barrett CPA, Consultant (Age 43) What is Assembly Biosciences' stock symbol? Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB." Who are Assembly Biosciences' major shareholders? Assembly Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Emerald Advisers LLC (1.35%), Emerald Mutual Fund Advisers Trust (1.05%), Valeo Financial Advisors LLC (0.10%), National Asset Management Inc. (0.04%), SG Americas Securities LLC (0.04%) and UBS Group AG (0.02%). Company insiders that own Assembly Biosciences stock include Jacqueline Sybil Papkoff, Richard James Colonno and Uri A Lopatin. View institutional ownership trends for Assembly Biosciences. Which major investors are selling Assembly Biosciences stock? ASMB stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Valeo Financial Advisors LLC, and National Asset Management Inc.. Company insiders that have sold Assembly Biosciences company stock in the last year include Jacqueline Sybil Papkoff, and Richard James Colonno. View insider buying and selling activity for Assembly Biosciences. Which major investors are buying Assembly Biosciences stock? ASMB stock was acquired by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, and SG Americas Securities LLC. View insider buying and selling activity for Assembly Biosciences. How do I buy shares of Assembly Biosciences? Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Assembly Biosciences' stock price today? One share of ASMB stock can currently be purchased for approximately $22.20. How big of a company is Assembly Biosciences? Assembly Biosciences has a market capitalization of $726.38 million and generates $15.96 million in revenue each year. The biopharmaceutical company earns $-97,630,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Assembly Biosciences employs 95 workers across the globe. What is Assembly Biosciences' official website? The official website for Assembly Biosciences is www.assemblybio.com. How can I contact Assembly Biosciences? Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
